Anti-vascular endothelial growth factor (VEGF) agents in combination with immunotherapies have improved outcomes for cancer patients, but predictive biomarkers have not been elucidated. We report here ...
Twice-Weekly Paclitaxel and Weekly Carboplatin With Concurrent Thoracic Radiation Followed by Carboplatin/Paclitaxel Consolidation for Stage III Non–Small-Cell Lung ...
Expert Rev Ophthalmol. 2008;3(3):311-323. The new and promising strategies for treating CNV include the use of drugs against VEGF, in particular isoform A, which is the most potent promoter of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results